EndoPredict for breast cancer - the company chose not to participate with data

TLV

19 August 2021 - In November 2020, Myriad Genetics chose to refrain from participating in a health economic assessment of EndoPredict. 

TLV has therefore not performed any such assessment.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder